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Disease advocacy organizations have long played an important role in the continuum from
basic science to therapy development in rare disease research. PXE International has
led the ﬁeld in innovative ways, venturing into speciﬁc activities that have traditionally
been conducted by scientists. As lay founders, we have engaged in gene discovery, gene
patenting, diagnostic test development, epidemiological studies, clinical trials, and therapy
research and development. This article will describe the steps that we took, and the ways
in which we have scaled these efforts for the larger community.
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ONE DISEASE
This perspective is that of individuals, families, and communi-
ties engaging in the scientiﬁc process to accelerate and improve
health. We are ordinary parents, like hundreds working to better
the lives of their children. Our original focus on our children’s
disease has become agnostic to disease, and expanded to include
broad systemic change in the clinical and translational research
enterprise.
Our quest began in 1993, when we noticed some small lesions
on the sides of our 7-year-old daughter Elizabeth’s neck. After a
year of the diagnostic odyssey, we took her, out of plan and out
of pocket, to a dermatologist, Lionel Bercovitch, MD, who rec-
ognized pseudoxanthoma elasticum (PXE) immediately. Looking
at Elizabeth’s 5-year-old brother, Ian’s neck, and said, “He has
it too.” Then he examined Elizabeth’s eyes. He was the perfect
diagnostician for this condition; he was also trained as an oph-
thalmologist. Before this experience, we had no idea that a skin
disease could be systemic. We had no frame of reference for all
of this foreign information: “systemic, genetic, recessive, papules,
angioid streaks. . .”
Our response, besides showering our children with gifts that
Christmas 1994, in the pre-internet age, was to photocopy every
articlewe couldﬁndon thedisease: a stack of about 400 articles.We
could not understand them and so turned to medical dictionaries
and reference material.
By the middle of January, we understood several important
things: (1) no one knew how this disease progressed, there were
conﬂicting conclusions in the papers we read, (2) there was no
comprehensive plan to study the disease, nor was there a plan
emerging, (3) no one even knew how many people had the dis-
ease, and (4) there was no treatment, the gene had not even been
discovered yet!
In the midst of this morass, two researchers from two different
prominent biomedical research institutions appeared. After the
ﬁrst took blood from all of us, the second wanted the same. We
told him to go get some from the ﬁrst one. The chuckled and we
learned the astounding fact that that scientists competed: they did
not collaborate.
Within a few months of the start of our informal educa-
tion in PXE, genetics, dermatology, ophthalmology, cardiology,
biomedical research, and therapy development, we devised a plan
largely inﬂuenced by Patrick’s background in building engineer-
ing. Figure 1 shows the “wiring diagram” plan for advancing
research to lead to interventions (Terry and Boyd, 2001).
We ﬁrst enlisted Dr. Bercovitch, asking him to be medical
director and board member of a foundation we named PXE Inter-
national. Then we asked the nearest lab engaged in the search for
the PXEgene, if we couldwash test tubes to speedup their research.
They generously allowed us to come into the lab in the evenings
and eventually gave us keys. They did not want us washing test
tubes, they wanted us to “score gels.” And so we scored gels night
after night. Patrick often stayed until the wee hours of the morn-
ing. We had a wonderful neighbor who would watch our kids in
the evenings while they slept.
Simultaneous with this we started to build a cohort of well-
characterized individuals affected by PXE.We contacted dermatol-
ogists and ophthalmologists around the world and started adding
people to our registry. We held meetings in Boston, New York,
California, Paris, Gent, Modena, Amsterdam, and Cape Town. We
used the nascent internet and created listservs.
We also contacted all of the researcherswhohadwritten numer-
ous papers on PXE. We asked if we could meet with them, and to
a person, they were generous and open with their time. Ken Neld-
ner (Neldner, 1988), Mark Lebwohl (Lebwohl et al., 1994), Jouni
Uitto (Christiano et al., 1992; Christiano and Uitto, 1994), Anne
De Paepe (Godfrey et al., 1995), Ivonne Ronchetti (Contri et al.,
1996), Charles Boyd (Lebwohl et al., 1994), Arthur Bergen (van
Soest et al., 1997), Michael Pope (Pope, 1975), and Dennis Viljoen
(Viljoen, 1988), all met with us in their labs, gave us tours and
educated us.
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FIGURE 1 | PXE International’s 1995 Strategic Plan (published inTerry and Boyd, 2001).
We recommended to the researchers that they all work together
to ﬁnd the gene. People told us“you can’t herd cats, so stop trying.”
We retorted, “yes you can, you just need to move the food.” We
set to work building the ﬁrst ever lay-owned blood and tissue
bank (Terry et al., 2007; Terry, 2008). We collected blood samples
by sending kits to affected individuals all over the world. With
epidemiologists, we created a survey instrument and administered
it, including collecting pedigrees. We then gave researchers access
to the de-identiﬁed samples and data if they agreed to play by our
then novel data sharing rules.
We had some sophisticated help in those days. Having met
Francis Collins, then director of the National Human Genome
Research Institute (NHGRI) at the National Institutes of Health,
at the 10th anniversary of the Alliance of Genetic Support Groups
(now known as Genetic Alliance), we asked for advice and
he shared NHGRI’s technology transfer wizard with us. Claire
Driscoll helped us craft state of the art consents, protocols, mate-
rial transfer agreements, and then joined our board upon which
she still serves. The work she did formed the underpinning of our
later cross-disease efforts.
We were not able to get all research groups to share data in
those early days, but we did get a few to combine forces resulting
in back-to-back papers in Nature Genetics (Bergen et al., 2000;
Le Saux et al., 2000) when the gene was discovered through our
wet bench work and that of several other groups (Ringpfeil et al.,
2000). We were also able to encourage focus on the discovery of
the gene associated with PXE, despite the attractiveness of several
unknown genes in the locus. This is evidence of the contributions
communities can make even in basic research related to a disease.
Our work moved from scoring gels to entering and analyzing
the data, meeting with the various teams around the world search
for the gene, and materially participating in the discovery. With a
group of about ﬁve scientists we discovered the: one of the known
ones-ABCC6. This discovery taught us a very important lesson.
It was thought that the gene would code for a protein involved
in a structural aspect of elastin, since degredated elastin ﬁbers are
common in all of the organs affected by PXE. Instead, ABCC6
codes for a membrane transport protein, in the same family as
cystic ﬁbrosis. The big learning for us, which we encounter over
and over in biology, is that we do not know which discoveries are
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going to beneﬁt one disease or another. We often quote: “a rising
tide lifts all boats.” This experience was critical to our thinking
about this disease and others on a system level. It later informed a
policy positionGeneticAlliance took about not earmarking federal
funds for speciﬁc diseases (Terry, 2010).
We are co-inventors and patent holders of ABCC6 with the
other scientists. We have assigned our rights to PXE International
and as such are stewards of the gene, making sure there is open
access to it for research and therapeutic development.
ALL DISEASES
Throughout these years, we frequently met with individuals
affected by PXE and their families around the world. We built
a robust website at pxe.org and created volumes of information
on the disease to help mitigate the diagnostic odyssey and lack of
information.
From the beginning we had excellent mentors in disease advo-
cacy organizations.We also had hundreds of requests to help other
organizations set up registries, biobanks, and research enterprises.
I moved my work to a dynamic umbrella organization called
Genetic Alliance, and was joined by remarkable colleagues who
also sought the most effective systems-level solutions to accelerate
translational research and services for all. Together we created a
collaborative network that has led to the development of many
tools, resources, and even legislation (Table 1).
CULTURE CHANGE
Changes taking place in society in the areas of information tech-
nology and networks, if parlayed for improving health, will be an
essential catalyst for the transformation of biomedical research.
The current biomedical research system was modeled after an
industrial age culture of scarcity, win–lose, linear progress, and
competition. We live in an age where raw materials are abundant:
information is being produced today at rates we cannot manage.
A newborn has more information shared about her in the ﬁrst
days of life than the US Library of Congress contains. Networks,
concurrent processes, win–win engagements, and ever increas-
ing transparency and openness are now available to transform the
research enterprise.
These changes have initiated a wonderful rebirth in systems
surrounding non-proﬁts such as Genetic Alliance. It is critical for
us to work with other organizations in a boundary-less way. This
requires that we ask “how is it true of me?” when we encounter
an obstacle that appears to be external. This is our practice both
as individuals in Genetic Alliance and PXE International and for
the organizations themselves. It is our belief that each of us is
responsible because we not only represent the whole: we are the
whole. It is also critical for us to be ever vigilant of the downfall of
all systems: that they begin to exist to largely to protect the system
rather than to serve the mission (Meadows, 2008). Just as we each
look in the mirror every day and ask, “Am I the best person for
Table 1 | Resources and tools to accelerate research and services.
Need Tool or resource Year Reference
Cross-disease, common platform, biobank, and registry Genetic Alliance Registry and BioBank
(www.biobank.org)
2003 Landy et al. (2012)
Toolbox/manual for maintaining an advocacy organization WikiAdvocacy (www.wikiadvocacy.org) 2004 Weiss (2004)
Disease information provided by the experts (disease advocacy
organizations) and ﬁltered from federal sources to be at the right
literacy level
Disease InfoSearch
(www.diseaseinfosearch.org)
2006, revised
in 2013
Landy et al. (2012)
The power of family history Does It Run in the Family?
(www.familyhealthhistory.org)
2006 O’Leary et al. (2011)
Protection against discrimination based on genetics Coalition for Genetic Fairness and passage
of the Genetic Information
Nondiscrimination Act of 2008
(www.ginahelp.org)
2008 Dressler andTerry
(2009); Terry (2009)
Clarity about the reliability of health information on the internet Trust It or Trash It (www.trustortrash.org) 2009 NA
Information about newborn screening in all 50 states Baby’s First Test (www.babysﬁrsttest.org)
as a result of the Newborn Screening
Saves Lives Act of 2008
2010 NA
Drug development seen as a network, rather than a pipeline Navigating the Ecosystem of Translational
Science (www.geneticalliance.org/nets)
2011 Baxter et al. (2013)
Cross-disease registries for all that allow the individual to set
their sharing and data access settings
Registries for All (www.reg4all.org) 2013 Terry et al. (2013)
Clinical trials need to ﬁnd the individual, not the other way around TrialsFinder (www.trialsﬁnder.org) 2013 NA
Resources for the public to understand genetic technologies Genes In Life (www.genesinlife.org) 2013 NA
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this job?,” it is critical we ask if Genetic Alliance or PXE
International are the best organization for their respective
missions.
THE FUTURE
Advocacy organizations of the future will not look like today’s
organizations that were built on models such as Alcoholics
Anonymous. Today’s young parents do not join one group, one
organization. They join many afﬁnity groups and are adept at
managing them. They create custom solutions that meet their
family’s needs. They use multiple ways of interacting, without
compartmentalizing their lives. They do not experience the same
level of isolation based on their children’s diagnosis as we did in
1994. Parents today do not identify with one aspect of life to the
detriment of others.
It’s never wise to predict the future. I do believe, however, that
we need to be bold in our vision of the future. I think that if we
do not risk it all, and lead to the highest place we can envision,
we will not succeed in our lofty, and essential, goals. I believe that
we need to work together, without regard for the histories of our
organizations, or body geography of the diseases for which we seek
to ﬁnd therapies.
Tools to help us achieve grand challenges have emerged. Data
sharing in the information age is transformative – it will break
down barriers and accelerate translational and clinical science.
Giving individuals and communities the tools to decide with
whom to share their data and samples, and how much to share
is essential. When we understand that our fear of sharing infor-
mation is hugely detrimental to accelerating solutions we will free
up a great deal of energy. The old system will not work. Advocacy
organizations, academic institutions, companies, and legislators
still cling to it since it is familiar and safe. It is hard for us to see
howunsafe it is to remain in the oldmodels, and that it will impede
our efforts. We have ample examples in other industries: music,
travel, and publishing. Consumers have effected that change. As
consumers in the cottage industry we call healthcare we are dis-
connected from our needs, and cannot feel them in the same way
as we feel the need for music or air travel options and accessibility.
This is remarkable because so much is at stake. Special inter-
ests, uncoordinated systems, lack of evidence, a “non-learning”
healthcare system and fear keep us from achieving better health
for all.
The advocacy organizations of the future will be ﬂexible and
dynamic. Their boards of directors will not focus on sustaining
the organization; they will focus on maximizing the advance to
the goals. They will be cross-disease, and be constellated around
biological pathways, phenotypes, and biomarkers. They will come
into being to address a very critical problem and dissolve or move
on once that problem is addressed. The advocacy organization of
the future will be an integral part of the research enterprise and
not so novel in its work that it would be worthy of this sort of
paper.
It is time to align incentives to serve the millions around the
globe who suffer. It is time to risk what we think is unthinkable,
share information and be bold. There is no time to hesitate – our
loved ones cannot wait.
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